Advertisement

Aging Clinical and Experimental Research

, Volume 30, Issue 1, pp 81–87 | Cite as

The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy

  • Giulia Scondotto
  • Fanny Pojero
  • Sebastiano Pollina Addario
  • Mauro Ferrante
  • Maurizio Pastorello
  • Michele Visconti
  • Salvatore Scondotto
  • Alessandra CasuccioEmail author
Original Article

Abstract

Aim

Primary endpoint was to report polypharmacy distribution in the general population vs ≥65 years old people and to examine the frequency of drug–drug interactions (DDIs) in the Health Local Unit of Palermo, Italy, in relationship with patients’ age.

Methods

Drug prescription data for the year 2014 were extracted from the database of the Local Health Unit of Palermo Province, Italy. Patients were divided into five age groups (0–13, 14–64, 65–69, 70–74, and ≥75 year old). The detection of potential DDIs in polypharmacy profiles was performed with NavFarma software (Infologic srl, Padova, Italia), with DDI classification provided by tool Micromedex Drug Reax (Truven Health Analitics, Michigan, USA).

Results

We analyzed data of 1,324,641 patients, and 15,801,191 medical prescription were recorded; of these, 11,337,796 regarded chronic conditions. The drug prescriptions reached the highest values in the 65–69 and 70–74 age groups (p = 0.005 and p = 0.008 vs age 14–64 respectively). An overall amount of 6,094,373 DDIs were detected, of which 47,173 were contraindicated. Median number of DDIs was higher in 65–69 and 70–74 age groups (p = 0.008 and p = 0.012 vs age 14–64, respectively). Regarding contraindicated DDIs a significant difference was detected comparing 14–64 vs ≥65 age groups (p = 0.010 vs 65–69 group, p = 0.005 vs 70–74 group and ≥75 group).

Conclusions

Polypharmacy is a phenomenon acquiring increasing dimensions also in our province. It interests particularly the older subjects, and assumes a dramatic accent when it is put in relationship with the frequency of DDIs. A proactive vigilance about potential life threatening drug interactions is mandatory.

Keywords

Polypharmacy Drug interactions Elderly population Drug prescriptions Contraindicated drug–drug interactions 

Notes

Compliance with ethical standards

Author contributions

GS, SPA, AC designed research; GS, FP, MP, MV performed research; SPA, MF, SS analyzed data; GS, FP, AC wrote the paper.

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval

The study was approved by the Ethics Committee of the Azienda Ospedaliero-Universitaria Policlinico “Paolo Giaccone” in Palermo, Italy.

References

  1. 1.
    Munger MA (2010) Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus. Drugs Aging 27:871–883CrossRefPubMedGoogle Scholar
  2. 2.
    Peron EP, Ogbonna KC, Donohoe KL (2015) Antidiabetic medications and polypharmacy. Clin Geriatr Med 31:17–27CrossRefPubMedGoogle Scholar
  3. 3.
    Calandre EP, Rico-Villademoros F, Rodríguez-López CM (2012) Monotherapy or combination therapy for fibromyalgia treatment? Curr Rheumatol Rep 14:568–575CrossRefPubMedGoogle Scholar
  4. 4.
    Brandi ML (2012) Drugs for bone healing. Expert Opin Investig Drugs 21:1169–1176CrossRefPubMedGoogle Scholar
  5. 5.
    Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM (2016) Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol 7:346–353CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kim JH (2015) Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol 21:5158–5166CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    French JA, Faught E (2009) Rational polytherapy. Epilepsia 50(Suppl 8):63–68CrossRefPubMedGoogle Scholar
  8. 8.
    Füllhase C, Schneider MP (2016) 5-Alpha-reductase inhibitors and combination therapy. Urol Clin North Am 43:325–336CrossRefPubMedGoogle Scholar
  9. 9.
    Corsonello A, Abbatecola AM, Fusco S, Luciani F, Marino A, Catalano S, Maggio MG, Lattanzio F (2015) The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol Infect 21:20–26CrossRefPubMedGoogle Scholar
  10. 10.
    Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K (2016) Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging 11:423–435PubMedPubMedCentralGoogle Scholar
  11. 11.
    Wiznia LE, Federman DG (2016) Treatment of basal cell carcinoma in the elderly: what nondermatologists need to know. Am J Med 129:655–660CrossRefPubMedGoogle Scholar
  12. 12.
    Welker KL, Mycyk MB (2016) Pharmacology in the geriatric patient. Emerg Med Clin North Am 34:469–481CrossRefPubMedGoogle Scholar
  13. 13.
    Dharmarajan TS, Dharmarajan L (2015) Tolerability of antihypertensive medications in older adults. Drugs Aging 32:773–796CrossRefPubMedGoogle Scholar
  14. 14.
    Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101–119CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, Bereznicki LR (2016) Hospitalization in older patients due to adverse drug reactions-the need for a prediction tool. Clin Interv Aging 11:497–505CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wajne EJ (1958) In: Walpole AL, Spinks A (eds) The evaluation of drug toxicity. London, Churchill, pp 1–11Google Scholar
  17. 17.
    Cadieux RJ (1989) Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 86:179–186CrossRefPubMedGoogle Scholar
  18. 18.
    Marengoni A, Pasina L, Concoreggi C, Martini G, Brognoli F, Nobili A, Onder G, Bettoni D (2014) Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med 25:843–846CrossRefPubMedGoogle Scholar
  19. 19.
    Wallace J, Paauw DS (2015) Appropriate prescribing and important drug interactions in older adults. Med Clin North Am 99:295–310CrossRefPubMedGoogle Scholar
  20. 20.
    Gómez-Huelgas R, Giner-Galvañ V, Mostaza JM, Cuende JI, de Miguel-Yanes JM, Rovira E, Sánchez-Fuentes D, Suárez Fernández C, Román Sánchez P; SEMI Working Group (2014) Unanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish Society of Internal Medicine. BMC Cardiovasc Disord 14:193CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S (2016). Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open 6:e010989CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bjerrum L, Rosholm JU, Hallas J, Kragstrup J (1997) Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 53:7–11CrossRefPubMedGoogle Scholar
  23. 23.
    Onder G, Bonassi S, Abbatecola AM, Folino-Gallo P, Lapi F, Marchionni N, Pani L, Pecorelli S, Sancarlo D, Scuteri A, Trifirò G, Vitale C, Zuccaro SM, Bernabei R, Fini M; Geriatrics Working Group of the Italian Medicines Agency (2014) High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci 69:430–437CrossRefPubMedGoogle Scholar
  24. 24.
    Nobili A, Pasina L (2014) Pharmacological treatment of complex elderly patients: drug interactions. Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione 6:38–45. Website: http://www.sefap.it/web/upload/GIFF3_2014_05_Nobili_ras_1.pdf. Last accessed 29 Nov 2016
  25. 25.
    Website: http://www.istat.it/it/sicilia. Last accessed 29 Nov 2016
  26. 26.
  27. 27.
    Page AT, Potter K, Clifford R, Etherton-Beer C (2016) Deprescribing in older people. Maturitas 91:115–134CrossRefPubMedGoogle Scholar
  28. 28.
    Lavan AH, Gallagher PF, O’Mahony D (2016) Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging 11:857–866PubMedPubMedCentralGoogle Scholar
  29. 29.
    Lavan AH, Gallagher P (2016) Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 7:11–22CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mukete BN, Ferdinand KC (2016) Polypharmacy in older adults with hypertension: a comprehensive review. J Clin Hypertens (Greenwich) 18:10–18CrossRefGoogle Scholar
  31. 31.
    United Nations, Department of Economic and Social Affairs, Population Division: World population ageing: 1950–2050 (2002) World assembly on ageing. http://www.un.org/esa/population/publications/worldageing19502050/. United Nations Publications, New York. Accessed 29 Nov 2016
  32. 32.
    United Nations World Population Ageing 2013 (2013) UN, New YorkGoogle Scholar
  33. 33.
    Gruppo Tecnico di Coordinamento del Sistema di Sorveglianza PASSI d’Argento. Luzi P (ed) Sperimentazione PASSI d’Argento (Progressi delle Aziende Sanitarie per la Salute in Italia): verso un sistema nazionale di sorveglianza della popolazione ultra64enne. Roma: Istituto Superiore di Sanità; 2013. (Rapporti ISTISAN 13/9). Website: http://www.iss.it/binary/publ/cont/13_9_web.pdf. Last accessed 29 Nov 2016

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Giulia Scondotto
    • 1
  • Fanny Pojero
    • 1
  • Sebastiano Pollina Addario
    • 2
  • Mauro Ferrante
    • 3
  • Maurizio Pastorello
    • 4
  • Michele Visconti
    • 4
  • Salvatore Scondotto
    • 2
  • Alessandra Casuccio
    • 1
    Email author
  1. 1.Dipartimento di Scienze per la Promozione della Salute e Materno Infantile “G. D’Alessandro” Università di PalermoPalermoItaly
  2. 2.Dipartimento Attività Sanitarie e Osservatorio EpidemiologicoPalermoItaly
  3. 3.Dipartimento Culture e SocietàUniversità di PalermoPalermoItaly
  4. 4.Dipartimento FarmaceuticoASP PalermoPalermoItaly

Personalised recommendations